NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer

Phase 3

Completed

Conditions: Stage II Colon Cancer
Stage III Colon Cancer

Interventions: Drug: leucovorin calcium
Drug: fluorouracil
Other: laboratory biomarker analysis
Drug: oxaliplatin

First Posted Date: 2003-05-14

Last Posted Date: 2013-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2472

Registration Number: NCT00004931

Locations: 🇺🇸
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2003-05-08

Last Posted Date: 2014-01-06

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004094

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Monroe Medical Associates, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 1 locations

Sequential Vaccinations in Prostate Cancer Patients

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)
Drug: Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)
Drug: Recombinant Fowlpox-GM-CSF
Drug: Recombinant Human GM-CSF

First Posted Date: 2003-05-07

Last Posted Date: 2017-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00060528

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Phase 2

Completed

Conditions: Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Ovarian Undifferentiated Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Brenner Tumor
Ovarian Clear Cell Cystadenocarcinoma
Fallopian Tube Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: erlotinib

First Posted Date: 2003-05-07

Last Posted Date: 2015-12-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00059787

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Mucinous Adenocarcinoma of the Rectum
Signet Ring Adenocarcinoma of the Colon
Stage IIIC Rectal Cancer
Mucinous Adenocarcinoma of the Colon
Stage IIIA Colon Cancer
Stage IIIA Rectal Cancer
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Rectum
Stage IIIB Rectal Cancer
Stage IVB Colon Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Biological: bevacizumab

First Posted Date: 2003-05-07

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00060411

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Phase 1

Terminated

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

Interventions: Biological: oblimersen sodium
Drug: gemcitabine hydrochloride
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-05-07

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00060112

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00060437

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: tipifarnib
Other: laboratory biomarker analysis

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00060125

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIA Non-small Cell Lung Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: motexafin gadolinium
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00005065

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Phase 2

Completed

Conditions: Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Biological: recombinant interferon alfa
Biological: oblimersen sodium
Other: pharmacological study

First Posted Date: 2003-05-07

Last Posted Date: 2013-08-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00059813

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Home Terms & Conditions Privacy Policy